Abionyx Pharma announces the appointment of Rob Scott as Chief Medical Officer (CMO) and Head of R&D, effective immediately, to bring to the biotech company his extensive experience in clinical and regulatory development.

Rob Scott has held senior positions in the global pharmaceutical industry and in emerging biotechs for over thirty years, including as Chief Medical Officer at AbbVie.

In his latter role, he was responsible for some forty new molecular entities, 4,000 people and a budget of around three billion dollars. He successfully oversaw the development of drugs such as Skyrizi and Rinvoq.

Copyright (c) 2024 CercleFinance.com. All rights reserved.